Clinics and research in hepatology and gastroenterology最新文献

{"title":"QuantiFERON-Monitor as prognostic marker of mortality in patients with decompensated cirrhosis: A prospective cohort study","authors":"Alice Dongier ,&nbsp;Edouard Louis ,&nbsp;Jean-Philippe Loly ,&nbsp;Pierre Dandoy ,&nbsp;Odile Warling ,&nbsp;Anne Vijverman ,&nbsp;Jean Delwaide","doi":"10.1016/j.clinre.2026.102776","DOIUrl":"10.1016/j.clinre.2026.102776","url":null,"abstract":"<div><h3>Background</h3><div>Prognosis in decompensated cirrhosis is heterogeneous and may be influenced by cirrhosis-associated immune dysfunction.</div></div><div><h3>Aims</h3><div>To assess whether QuantiFERON-Monitor, a whole blood interferon-γ release assay, predicts short-term outcomes in patients with acute decompensated cirrhosis.</div></div><div><h3>Methods</h3><div>We conducted a prospective cohort study in two hospitals (March 2022-March 2023), enrolling 44 patients hospitalized for acute decompensated cirrhosis. QuantiFERON-Monitor testing measured interferon-γ release after immune stimulation during hospitalization. Patients were followed for 90 days for mortality, bacterial infection, and acute-on-chronic liver failure. Associations between interferon-gamma levels and outcomes were evaluated using Cox proportional hazards and logistic regression models.</div></div><div><h3>Results</h3><div>The median interferon-γ release was 56 IU/mL (1-366). Each 10 IU/mL increase was associated with a 12% relative reduction in 90-day risk of death or ACLF (HR 0.88, 95% CI 0.79-0.99; p=0.03). No deaths occurred in patients with Interferon-γ ≥ 100 IU/mL versus 39% mortality in those below (p=0.01). Interferon-γ levels were not significantly associated with infection or acute-on-chronic liver failure. Adding QuantiFERON-Monitor to the MELD-Na improved discrimination for early mortality or acute-on-chronic liver failure.</div></div><div><h3>Conclusions</h3><div>Baseline interferon-γ release measured by the QuantiFERON-Monitor is a prognostic marker of short-term poor outcome in acute decompensated cirrhosis, reflecting cellular immune dysfunction. This assay may complement existing prognostic tools. Further validation with a larger cohort is required.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102776"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146099936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemorrhagic jejunal vascular malformations with loop telangiectasia in Turner’s syndrome","authors":"Arthur Jourdain ,&nbsp;Romain Leenhardt ,&nbsp;Ingrid Popa ,&nbsp;Xavier Dray","doi":"10.1016/j.clinre.2026.102782","DOIUrl":"10.1016/j.clinre.2026.102782","url":null,"abstract":"<div><div>A 47-year-old woman with Turner’s syndrome was admitted to the emergency room with anemic syndrome and melena. She has a history of hypothyroidism, premature ovarian insufficiency and chronic iron deficiency. She reported previous overt gastrointestinal (GI) bleeding attributed to duodenal vascular lesions. Endoscopic treatment and blood transfusion were performed. She received estroprogestative therapy, thyroid hormone substitution and oral iron replacement therapy on the long run. Hemoglobin rate was 6.1 g/dL. Upper GI endoscopy was normal, colonoscopy showed blood clots in the ileum and in the right colon. Small bowel capsule endoscopy identified active jejunal bleeding. Both capsule endoscopy and deep enteroscopy identified multiple, tiny, looped telangiectasias in the duodenum and jejunum (Fig 1 and Fig 2) which were ablated using argon plasma coagulation. GI bleeding and iron deficiency recurred several times during the three years follow-up. Long-acting release octreotide treatment was initiated and progressively increased due to recurrent GI bleeding. Parenteral iron supplementation were performed. Further endoscopic investigations identified once again non hemorrhagic typical looped small bowel telangiectasias. Eradication treatment consisted in argon plasma coagulation. Case reports have described hemorrhagic GI vascular abnormalities responsible for longstanding iron deficiency anemia and overt GI bleeding in women with Turner’s syndrome.(1) These vascular lesions were predominantly (72%) located in the small bowel where they can be diagnosed with capsule or enteroscopy. Authors usually use the terms telangiectasia, prominent submucosal vascular network, and/or phlebectasia to describe these lesions. Reports describing abnormalities observed during laparoscopic evaluation mentioned segmentally distended veins on the serosal surface of the small and large bowel (1,2,3). Exceptional reports of perendoscopic biopsies mentioned superficial telangiectasia of the mucosa, and an enterectomy pathological analysis showed medium-sized ectasic, congestive vessels in the mucosa and serosa.(3) The small bowel microvasculature lesions reported in association with Turner’s syndrome thus differ from angiodysplasias. Angiodysplasias are typically described as flat lesions, consisting of tortuous and clustered capillary dilatations, within the mucosal layer (4) either seen in a sporadic manner or as observed in Osler-Weber-Rendu syndrome (4,6). Still, because loop telangiectasias in Turner’s syndrome are tiny, superficial vascular lesions, we attempted a similar treatment to that of angiodysplasia (5), with first-line (argon plasma coagulation) and second-line (long-acting release octreotide), resulting in significant biological improvement in our patient. At 6 months of follow-up after octreotide optimization, no recurrence occurred, hemoglobin rate was 14.1 g/dL with ferritinemia at 16 ng/mL.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102782"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146140603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generalizability and confounding in chemotherapy-induced hepatotoxicity: A call for robust risk stratification","authors":"Koji Takahashi","doi":"10.1016/j.clinre.2026.102785","DOIUrl":"10.1016/j.clinre.2026.102785","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102785"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary diffuse large B-cell lymphoma of the liver mimicking ruptured hepatocellular carcinoma with hemorrhage","authors":"Tian-Qi Zhao ,&nbsp;Wei Jiang ,&nbsp;Cun-Jin Ge ,&nbsp;Wei Liu","doi":"10.1016/j.clinre.2026.102786","DOIUrl":"10.1016/j.clinre.2026.102786","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102786"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146206291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modeling the importance of coenzyme Q9, glutathione and mitochondrial complex activity in a high fat diet model by a multivariate approach","authors":"Francisco Baez ,&nbsp;Damian Soria ,&nbsp;Mario Contin ,&nbsp;Carolina Caniffi ,&nbsp;Valeria Tripodi","doi":"10.1016/j.clinre.2026.102766","DOIUrl":"10.1016/j.clinre.2026.102766","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102766"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory ascites following pancreatoduodenectomy after preoperative oxaliplatin based chemotherapy: be aware of nodular regenerative hyperplasia!","authors":"Jennifer Candi ,&nbsp;Emma Zuppi ,&nbsp;Camille Besch ,&nbsp;Thibault Wolf ,&nbsp;Pietro Addeo","doi":"10.1016/j.clinre.2025.102753","DOIUrl":"10.1016/j.clinre.2025.102753","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 2","pages":"Article 102753"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FXR dysregulation as the metabolic nexus driving cholesterol gallstone disease","authors":"Sarvesh Sabarathinam ,&nbsp;Nila Ganamurali ,&nbsp;K K S Kartheekeyan ,&nbsp;Manoj Kumar Narasimhan ,&nbsp;Evelyn Sharon Sukumaran","doi":"10.1016/j.clinre.2026.102767","DOIUrl":"10.1016/j.clinre.2026.102767","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 2","pages":"Article 102767"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal calprotectin in patients with concomitant primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis","authors":"Giorgia Burrelli Scotti ,&nbsp;Fabrizio Zullo ,&nbsp;Marco Mattana ,&nbsp;Francesco Covotta ,&nbsp;Emanuela Ribichini ,&nbsp;Domenico Alvaro ,&nbsp;Vincenzo Cardinale","doi":"10.1016/j.clinre.2026.102764","DOIUrl":"10.1016/j.clinre.2026.102764","url":null,"abstract":"<div><h3>Background</h3><div>Primary sclerosing cholangitis (PSC) is strongly associated with inflammatory bowel disease (IBD), with up to 70% of PSC patients having concomitant IBD (PSC-IBD). Fecal Calprotectin (FC) is a validated surrogate biomarker of intestinal inflammation in IBD. Emerging evidence suggests that FC may also reflect biliary inflammation in PSC.</div></div><div><h3>Aim</h3><div>This study aimed to compare FC concentrations in patients with PSC-IBD versus IBD only.</div></div><div><h3>Methods</h3><div>A systematic literature search was performed (PROSPERO registration no. CRD42024600985). Studies reporting FC levels in both PSC-IBD and IBD-only patients were included. The outcome of interest was the difference in mean FC concentration between the two groups.</div></div><div><h3>Results</h3><div>Seven studies met the inclusion criteria. There was no significant difference in the mean FC levels between PSC-IBD and IBD patients (-5.10, 95% confidence interval [CI] -45.40 to -35.2; p= 0.8). The findings remained non-significant when endoscopic remission was considered (12.82, 95% CI -19.33 to 44.97; p= 0.43).</div></div><div><h3>Conclusions</h3><div>FC levels did not significantly differ between PSC-IBD and IBD groups. The available evidence is limited and heterogeneous. Larger, well-designed studies are needed to determine whether FC can serve as a surrogate biomarker of PSC progression, particularly in patients with endoscopic remission of colitis or without concomitant IBD.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 2","pages":"Article 102764"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of repeat hepatectomy with radiofrequency ablation for the survival of hepatocellular carcinoma with solitary intrahepatic recurrence after hepatectomy","authors":"Jialu Fu ,&nbsp;Jiafeng Chen ,&nbsp;Lei Jin ,&nbsp;Junfeng Huang ,&nbsp;Shengwei Mao ,&nbsp;Xuhui Zhao ,&nbsp;Weifeng Qu ,&nbsp;Rui Yang ,&nbsp;Yi Wang ,&nbsp;Yichao Bu ,&nbsp;Zhiqi Guan ,&nbsp;Jun Gao ,&nbsp;Xiaoling Wu ,&nbsp;Qianfu Zhao ,&nbsp;Tianhao Chu ,&nbsp;Guiqi Zhu ,&nbsp;Yuan Fang ,&nbsp;Yinghong Shi ,&nbsp;Weiren Liu","doi":"10.1016/j.clinre.2025.102750","DOIUrl":"10.1016/j.clinre.2025.102750","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare survival outcomes between repeat hepatectomy (RHT) and radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) patients with solitary intrahepatic recurrence after initial hepatic resection, and to identify associated prognostic factors.</div></div><div><h3>Patients and Methods</h3><div>This study included 377 HCC patients with solitary intrahepatic recurrence after initial hepatectomy (RHT=280, RFA=97). Propensity score matching (PSM) was used to balance intergroup characteristics. Survival outcomes (OS and rRFS) were analyzed using Kaplan-Meier method and compared by log-rank test. Variables that were significant in univariate analysis were further included in multivariate analysis.</div></div><div><h3>Results</h3><div>No significant differences were observed in either OS or rRFS between RFA and RHT groups before (<em>P</em> = 0.37 for OS; <em>P</em> = 0.30 for rRFS) or after PSM (<em>P</em> = 0.58 for OS; <em>P</em> = 0.76 for rRFS). Era-stratified analysis (earlier cohort [1996–2005]: <em>P</em> = 0.40 for OS, <em>P</em> = 0.62 for rRFS; later cohort [2006–2010]: <em>P</em> = 0.18 for OS, <em>P</em> = 0.08 for rRFS) confirmed this finding. Subgroup analyses confirmed the equivalent survival outcomes between RFA and RHT in patients with tumors ≤ 3 cm or &gt; 3 cm but ≤ 5 cm. Multivariate analysis identified HBsAg positivity and tumor diameter &gt; 2 cm as independent risk factors for OS, while recurrence time ≤ 24 months was an independent risk factor for both OS and rRFS.</div></div><div><h3>Conclusion</h3><div>RFA provides comparable OS and rRFS to RHT for HCC patients with solitary intrahepatic recurrence ≤ 5 cm after hepatic resection.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 2","pages":"Article 102750"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Comparison of repeat hepatectomy with radiofrequency ablation for the survival of hepatocellular carcinoma with solitary intrahepatic recurrence after hepatectomy”","authors":"Kanishka Harariya ,&nbsp;Thakur Rohit Singh ,&nbsp;Ankita Kalra ,&nbsp;Swarupanjali Padhi ,&nbsp;Fayaz Ahamed","doi":"10.1016/j.clinre.2026.102762","DOIUrl":"10.1016/j.clinre.2026.102762","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 2","pages":"Article 102762"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}